Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 1

Conditions

Multiple Myeloma 5Breast Neoplasms 4Vomiting 3Neoplasms 3Lymphoma, Non-Hodgkin 3Stomach Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm Metastasis 2Nausea 2Hodgkin Disease 2Hematologic Neoplasms 2Endometrial Neoplasms 2Burkitt Lymphoma 2Uterine Cervical Neoplasms 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Renal Insufficiency 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Postoperative Nausea and Vomiting 1Pathologic Complete Response 1Paraproteinemias 1Pain 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1NSCLC 1Mucositis 1Mastocytosis, Systemic 1

Interventions

Cyclophosphamide 240Rituximab 187fludarabine phosphate 129Etoposide 110Peripheral Blood Stem Cell Transplantation 108Mycophenolic Acid 94Filgrastim 91Melphalan 90Whole-Body Irradiation 88fludarabine 80Busulfan 80Tacrolimus 71Cytarabine 66Cyclosporine 66Radiotherapy 62Methotrexate 53Antilymphocyte Serum 53Granulocyte Colony-Stimulating Factor 51Vincristine 49Carmustine 48Doxorubicin 41Prednisone 37Thiotepa 33Bendamustine Hydrochloride 32Bortezomib 30Methylprednisolone 29Dexamethasone 28Stem Cell Transplantation 27thymoglobulin 26ibritumomab tiuxetan 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Non-Hodgkin × Diphenhydramine × Clear all
NCT00840853 2025-07-09

MULTIPRAT

Baylor College of Medicine

Phase 1 Active not recruiting
68 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00324467 2021-07-22

LYTPET

British Columbia Cancer Agency

Phase 2 Unknown
150 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡